Dr. Lyudmila A. Bazhenova
Claim this profileUC San Diego Moores Cancer Center
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
20 reported clinical trials
30 drugs studied
About Lyudmila A. Bazhenova
Education:
- Earned an MD from Nizhny Novgorod State Medical Academy, Russia.
Experience:
- Completed a Fellowship in Hematology and Oncology at Scripps Clinic, La Jolla, CA.
- Served a Residency in Internal Medicine at UCLA-VA Greater Los Angeles Healthcare System.
- Holds the position of Clinical Professor of Medicine at UC San Diego Moores Cancer Center.
- Acts as the Lung Cancer Unit Leader and Director of the Hematology Oncology Training Program at UC San Diego.
- Has over 15 years of experience in lung cancer management, emphasizing a multidisciplinary treatment approach and active clinical research involvement.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Lyudmila A. Bazhenova is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
CAB-ROR2-ADC + PD-1 Inhibitor
for Breast Cancer
This trial is testing a new targeted cancer treatment called CAB-ROR2-ADC in patients with advanced solid tumors. The drug seeks out cancer cells with a specific marker and delivers a potent treatment directly to them.
Recruiting1 award Phase 1 & 29 criteria
More about Lyudmila A. Bazhenova
Clinical Trial Related3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Lyudmila A. Bazhenova has experience with
- Carboplatin
- Pembrolizumab
- Pemetrexed
- Durvalumab
- PD-1 Inhibitor
- Repotrectinib (TPX-0005)
Breakdown of trials Lyudmila A. Bazhenova has run
Non-Small Cell Lung Cancer
Lung Cancer
Solid Tumors
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lyudmila A. Bazhenova specialize in?
Lyudmila A. Bazhenova focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Lyudmila A. Bazhenova currently recruiting for clinical trials?
Yes, Lyudmila A. Bazhenova is currently recruiting for 10 clinical trials in La Jolla California. If you're interested in participating, you should apply.
Are there any treatments that Lyudmila A. Bazhenova has studied deeply?
Yes, Lyudmila A. Bazhenova has studied treatments such as Carboplatin, Pembrolizumab, Pemetrexed.
What is the best way to schedule an appointment with Lyudmila A. Bazhenova?
Apply for one of the trials that Lyudmila A. Bazhenova is conducting.
What is the office address of Lyudmila A. Bazhenova?
The office of Lyudmila A. Bazhenova is located at: UC San Diego Moores Cancer Center, La Jolla, California 92093 United States. This is the address for their practice at the UC San Diego Moores Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.